Browsing Category
Dry Powder Inhalers (DPI)
Development of (Inhalable) Dry Powder Formulations of AS01B-Containing Vaccines Using Thin-Film…
AS01B is a liposomal formulation of two immunostimulants namely 3-O-desacyl-4́-monophosphoryl lipid A (MPL) and QS-21. The liposomal formulation of AS01B reduces the endotoxicity of MPL and the lytic activity of QS-21. The AS01B-adjuvanted Shingrix vaccine is marketed in a two-vial presentation,…
Read More...
Read More...
The role of intrinsic fines in the performance change of expired lactose carriers for DPI…
Dry powder inhalation offers a well-established administration route for either local or systemic drug delivery. Lactose-based powder blends still build the basis of respiratory drug delivery, despite of numerous emerging formulation approaches. The amount of fine lactose excipients, either…
Read More...
Read More...
Proof-of-Concept for Adjusted Surface Energies and Modified Fines as a Novel Concept in Particle…
Currently marketed dry powder inhaler (DPI) medicine lacks drug delivery performance due to insufficient powder dispersion. In carrier-based blends, incomplete drug detachment is typically attributed to excessive adhesion forces between carrier and drug particles. Adding force control agents (FCA)…
Read More...
Read More...
Half a Century of Technological Advances in Pulmonary Drug Delivery: A Personal Perspective
The last half century of pulmonary product development is reviewed in the context of the main drivers of innovation, technology development, and the advancement of science. A perspective on development timeframes, patent lifetimes, and the odds of success of developing of new inhaler technologies is…
Read More...
Read More...
Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial…
It has been hypothesized that simvastatin could be used to treat pulmonary arterial hypertension (PAH). This study is intended to formulate a simvastatin nanoparticle dry powder inhalation (DPI) formulation. Simvastatin nanoparticles were prepared via an emulsification and homogenization-extrusion…
Read More...
Read More...
Crystallization induced flower-like lactose as potential carriers for dry powder inhaler application
The study documents the flower-like lactose particles as potential carriers to improve Dry Powder Inhaler (DPI) efficiency. The lactose particles (LMx, LMf) are prepared by anti-solvent crystallization and compared with commercial lactose carriers (Inhalac 251; LMc). Formulations of 1.48% w/w drug…
Read More...
Read More...
Inhaled Dry Powder Mannitol Treatment in Pediatric Patients with Cystic Fibrosis: Evaluation of…
Background: Cystic fibrosis (CF) is a genetic disorder, in which defective clearance of airway secretions leads to progressive lung function loss. Inhaled mannitol is used to increase sputum and mucociliary clearance. There are little data from real-world studies on the effectiveness of mannitol in…
Read More...
Read More...
Influence of surface interaction between drug and excipient in binary mixture for dry powder inhaler…
The present study documents the drug-excipient incompatibility in the physical mixtures and its influence on bulk homogeneity and flowability for dry powder inhalers (DPI) applications. Binary mixtures with the model drugs (aceclofenac; salbutamol sulphate) and lactose monohydrate were prepared…
Read More...
Read More...
Engineered-inhaled particles: influence of carbohydrates excipients nature on powder properties and…
Pulmonary drug administration has long been used for local or systemic treatment due to several advantages. Dry powder inhalers emerge as the most promising due to efficiency, ecologic, and drug stability concerns. Coarse lactose-carrier is still the gold standard when inhalation powders are…
Read More...
Read More...
Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational…
The multi-drug resistance of Pseudomonas aeruginosa is an overwhelming cause of terminal and persistent lung infections in cystic fibrosis (CF) patients. Antimicrobial synergy has been shown for colistin and ivacaftor, and our study designed a relatively high drug-loading dry powder inhaler …
Read More...
Read More...